Eurasian patent for technology for the production of immunoglobulin for the treatment of COVID-19

The global easing of the regime of preventive measures against coronavirus infection after almost two years of the pandemic does not yet guarantee a regime of absolute calm. The COVID-19 virus and its evolving strains remain, although already familiar, still a significant threat.

Against this background, Russian scientists continue to protect with patents new methods for obtaining components of possible drugs for the prevention and treatment of coronavirus infection, improving both their effectiveness and reducing the cost of obtaining such components.
A new method for producing immunoglobulin G, for which Eurasian patent No. 044535 was issued in August, was developed by the National Immunobiological Company.
The process of obtaining a patented component includes the selection of donor plasma, alcohol fractionation of plasma to obtain precipitate II+III according to Cohn, dissolution of the resulting precipitate II+III in a buffer solution, viral solvent-detergent inactivation and chromatographic purification.
It was the use of blood components containing antibodies to SARS-CoV-2 that became one of the first solutions that doctors around the world proposed for the prevention and control of COVID-19. Over the long months of the pandemic, the proposed method has repeatedly proven its effectiveness, which also depended on the receipt of the starting components.
The method of Russian scientists, protected by a Eurasian patent, uses a simpler and more routine analytical method for collecting plasma samples — enzyme-linked immunosorbent assay (ELISA), which allows testing a large number of plasma samples in a short time.
The drug obtained according to the technology has a higher degree of viral safety compared to analogues and contains 6-22 times more diverse antibodies than the original plasma, which provides a wider range of antiviral activity and makes drugs based on immunoglobulin G much more effective.